If this is also true for SARS-CoV-2 entry into host cells, it is possible that the release of mortalin in COVID-19 patients into their blood, accompanied by reduced intracellular mortalin levels, makes the patients’ cells more exposed to SARS-CoV-2 virus entry. This evidence concerns the gene HSPA9 and COVID-19.